Across TCGA pan-cancer cohorts, TMEM235 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM235 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM235 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM235 expression acts as an unfavorable survival marker.

LIHC and UCEC are the cancer types where TMEM235 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.093	0.783	<.001	30	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMEM235 tumor-vs-normal RNA expression · all TMEM235 data types